Market Overview

UPDATE: Barclays Raises PT to $57 on CVS Caremark Following Meeting with Management

Share:
Related CVS
What Tidings From the Tetons? Long-Awaited Yellen Speech Today
Analysts At Argus Review CVS Q2 Earnings
Mylan Expands Discount Program For EpiPen; PBM Stocks Under Pressure (Investor's Business Daily)

Barclays reiterated its Overweight rating on CVS Caremark (NYSE: CVS) and raised its price target from $54 to $57.

Barclays noted, "At CVS Caremark's 2012 analyst meeting, management showed investors how the company's business model gives it meaningful competitive advantages as the US healthcare industry is transformed. [P]erhaps most significant, is the change in rationale for payments to healthcare providers, especially doctors and hospitals, as the nation moves from fee-for-service to outcomes-based payment. We see many approaches to pay-for-performance, but encouraging patients to remain adherent to their medications is crucial to all of them."

CVS Caremark closed at $49.24 on Friday.

Latest Ratings for CVS

DateFirmActionFromTo
Aug 2016CitigroupMaintainsNeutral
Aug 2016Deutsche BankMaintainsHold
Jun 2016Morgan StanleyDowngradesEqual-weight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!